Prescribing information for BENLYSTA (belimumab), a BLyS-specific inhibitor for SLE and lupus nephritis, covering dosage, administration, warnings, and safety.
BENLYSTA (belimumab) is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for patients 5 years of age and older with active systemic lupus erythematosus (SLE) or active lupus nephritis who are receiving standard therapy. Its efficacy has not been evaluated in patients with severe active central nervous system lupus, and use is not recommended in that situation. BENLYSTA may be administered intravenously or subcutaneously; vials are for intravenous use only, while autoinjectors and prefilled syringes are for subcutaneous use only.
The document provides recommended dosages by route and patient population, preparation and dilution instructions, contraindications, warnings and precautions, adverse reactions, and other prescribing information. Common adverse reactions include nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, and injection site reactions. Serious infections, hypersensitivity reactions including anaphylaxis, depression and suicidality, and immunization precautions are addressed in the warnings and precautions.
| Intravenous dosage | 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter |
|---|---|
| Intravenous infusion duration | 1 hour |
| Subcutaneous dosage, adults with SLE | 200 mg once weekly |
| Subcutaneous dosage, pediatric patients with SLE weighing at least 40 kg | 200 mg once weekly |
| Subcutaneous dosage, pediatric patients with SLE weighing 15 kg to less than 40 kg | 200 mg once every 2 weeks |
| Subcutaneous dosage, adults with lupus nephritis | 400 mg once weekly for 4 doses, then 200 mg once weekly thereafter |
| Intravenous vial strengths | 120 mg or 400 mg belimumab lyophilized powder |
| Subcutaneous injection strength | 200 mg/mL belimumab |
| Reconstituted intravenous solution concentration | 80 mg/mL belimumab |
| Reconstitution volume, 120-mg vial | 1.5 mL Sterile Water for Injection, USP |
| Reconstitution volume, 400-mg vial | 4.8 mL Sterile Water for Injection, USP |
| Intravenous dilution volume | 250 mL, or 100 mL for patients weighing 40 kg or less |
| Maximum belimumab concentration in infusion bag | 4 mg/mL |
BENLYSTA is indicated for patients 5 years of age and older with active systemic lupus erythematosus (SLE) or active lupus nephritis who are receiving standard therapy.
The recommended intravenous dosage is 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter, administered as an infusion over 1 hour.
Common adverse reactions include nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, and injection site reactions.
No, live vaccines should not be given concurrently with BENLYSTA.